3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
53
Gastrointestinal
46
Genitourinary
26
Dermatologic
21
Head & Neck
18
Gynecologic
17
Breast
13
Lymphoid
5
Other solid neoplasm
4
Endocrine
2
Sarcoma
1
NET
1
CNS
1
Conditions
Glioblastoma
472
Brain Neoplasms
306
Glioma
257
Neoplasms
122
Astrocytoma
88
Carcinoma, Non-Small-Cell Lung
76
Breast Neoplasms
70
Neuroblastoma
65
Central Nervous System Neoplasms
61
Melanoma
58
Recurrence
46
Lung Neoplasms
45
Pancreatic Neoplasms
41
Oligodendroglioma
37
Ovarian Neoplasms
36
Colorectal Neoplasms
36
Neoplasm Metastasis
33
Sarcoma
32
Medulloblastoma
28
Stomach Neoplasms
27
Gliosarcoma
27
Lymphoma
25
Prostatic Neoplasms
24
Head and Neck Neoplasms
24
Neurofibromatosis 1
23
Rhabdomyosarcoma
21
Neurofibroma, Plexiform
19
Esophageal Neoplasms
19
Diffuse Intrinsic Pontine Glioma
19
Cholangiocarcinoma
19
Interventions
pembrolizumab
1
lenvatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
CNS
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts